Gerresheimer's June Litmus Test: Audit, Lawsuits, and the Wait for Creditor Certainty
14.06.2026 - 13:05:11 | boerse-global.de
The German audit oversight body APAS has opened a professional misconduct probe into KPMG, accusing the firm of signing off on Gerresheimer's 2024 annual accounts without qualification — despite €35 million in improperly recognized revenue embedded in the numbers. The move adds a regulatory front to an already crowded legal landscape surrounding the pharmaceutical packaging group, as the DSW shareholder protection association weighs compensation claims against former chief executive Dietmar Siemssen and ex-finance chief Bernd Metzner.
At the heart of the dispute lies a systematic booking error. Gerresheimer invoiced customers for goods before delivery, booking revenue too early in violation of IFRS rules. An independent law firm has confirmed the breaches, which distort €35 million in turnover and €24 million in adjusted EBITDA. The accounting mess also includes misstated lease liabilities, incorrect useful-life assumptions on capitalized development costs, and unrecognized impairment charges in the Advanced Technologies segment, where book value stands at nearly €197 million. A broader goodwill valuation of €676 million is also in the crosshairs.
These problems have pushed Gerresheimer into a race against time. The company has promised to publish its audited 2025 annual report by the end of June — a deadline that has already slipped past multiple earlier targets. Without that testat, the stock remains uninvestable for many institutional funds. The annual general meeting and first-quarter results were cancelled as the delay dragged on. The half-year report is scheduled for July 14, with third-quarter figures due October 15.
Creditors have granted breathing room but not forgiveness. Holders of €870 million in Schuldschein loans voted 96% in favor of extending maturities, and key covenant limits on leverage are suspended until September 30, 2026. Should the audit fail to materialize by then, financing pressure will spike. The company’s own revenue guidance of €2.3 billion to €2.4 billion for the current year remains contingent on a clean audit opinion.
Should investors sell immediately? Or is it worth buying Gerresheimer?
On the stock market, the tension is visible. Shares trade at €25.14, roughly 47% below their level twelve months ago and a staggering distance from the all-time high of €50.25. The stock was ejected from the SDAX index in April, removing a passive-buying constituency and further narrowing the base of long-term holders. Short interest has climbed to around 11.4%, well above the twelve-month average. While Arrowstreet Capital recently trimmed its short position, Millennium International Management LP increased its bearish bet.
Technically, the equity has clawed back from a February low of €14.90, but remains trapped in a narrow range. Support at €23.97 is providing a near-term floor, while the 50-day moving average at €25.64 caps any rally. Breaking above that level would signal a return of confidence; losing the support would risk a retest of the recent troughs.
Meanwhile, the macro backdrop is turning less forgiving. The European Central Bank has raised interest rates, and the U.S. Federal Reserve meets this week. In a world where borrowing costs are rising, investors demand predictability — exactly what Gerresheimer cannot yet deliver. The silence in the corporate calendar this week is not calm; it is a stress test of patience.
Gerresheimer at a turning point? This analysis reveals what investors need to know now.
Operationally, there are bright spots. The Peachtree City plant in Georgia has brought two automated pallet warehouses online, producing inhalers, autoinjectors, and infusion components. But that progress does not resolve the core crisis. All eyes remain fixed on June — the month that will either deliver the first credible financial data in months or leave Gerresheimer staring down an ever-tightening deadline with creditors, regulators, and shareholders all losing patience.
Ad
Gerresheimer Stock: New Analysis - 14 June
Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
